1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

ICER Hands CMS A Drug Price Negotiation Cheat Sheet On Eliquis, Xarelto

 
• By Jessica Merrill

Drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.

helping hand
ICER hopes to help CMS with its drug price negotiation program. • Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) is eager to help the US Centers for Medicare & Medicaid Services (CMS) navigate the intricacies of implementing a new drug price negotiation program. ICER has long run price and value assessments for drugs as an independent non-profit organization and has gained some influence in the US when it comes to drug pricing and the formulary negotiation process between drug manufacturers and insurers.

Key Takeaways
  • ICER conducted an evidence assessment of two drugs selected by CMS for the first round of drug price negotiations and submitted them to the government.
  • The comparative effectiveness analyses found Eliquis and Xarelto warrant a premium price over generic warfarin, but the price would likely be well below the current list prices of the two drugs

Now, ICER is hoping to use the experience it has gained conducting value assessments to guide CMS through a more formal process. ICER conducted an evidence assessment on two of the drugs selected by CMS for the first round of drug price negotiations – Pfizer Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Market Access

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.